Eicosanoids and inflammatory bowel disease.
IBD is a disease of unknown cause that involves an amplification of the inflammatory response in the intestinal mucosa. Although not the only offending agents leading to the disease, eicosanoids, the collective group of AA metabolites, may a significant role in the pathogenesis of IBD. This article reviewed the biochemical pathways of eicosanoid formation and the clinical relevance of eicosanoids to IBD. Potential strategies designed to interfere with various aspects of AA metabolism were also outlined. Further clinical trials of newer compounds may soon prove them effective in the management of IBD.
Yang
V W
VW
Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D016718:Arachidonic Acid / Q000037:antagonists & inhibitors / Q000378:metabolism; D015777:Eicosanoids / Q000037:antagonists & inhibitors / Q000378:metabolism*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism*; D016859:Lipoxygenase Inhibitors
D000893:Anti-Inflammatory Agents; D015777:Eicosanoids; D005938:Glucocorticoids; D016859:Lipoxygenase Inhibitors; D016718:Arachidonic Acid; D001094:Arachidonate 5-Lipoxygenase